• Users Online: 569
  • Print this page
  • Email this page

Table of Contents
Year : 2021  |  Volume : 18  |  Issue : 3  |  Page : 153

COVID-19 and neurological problems

1 Department of Neurosciences, Indraprastha Apollo Hospitals, New Delhi, India
2 Department of Orthopaedics and Joint Replacement Surgery, Indraprastha Apollo Hospitals, New Delhi, India

Date of Submission24-Aug-2021
Date of Acceptance24-Aug-2021
Date of Web Publication18-Sep-2021

Correspondence Address:
Pushpendra Nath Renjen
C-85, Anand Niketan, New Delhi - 110 021
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/am.am_101_21

Rights and Permissions

How to cite this article:
Renjen PN, Vaishya R. COVID-19 and neurological problems. Apollo Med 2021;18:153

How to cite this URL:
Renjen PN, Vaishya R. COVID-19 and neurological problems. Apollo Med [serial online] 2021 [cited 2021 Dec 6];18:153. Available from: https://www.apollomedicine.org/text.asp?2021/18/3/153/326241

The years 2020 and 2021 were difficult because of the COVID-19 pandemic. Sadly, it is still going on across the globe. Although it is primarily a respiratory disease, many other systems and organs are involved, including the neurological system.[1] Many acute and delayed neurological manifestations and complications of COVID-19 are encountered in a large number of cases.[2] Both the central and peripheral nervous system is involved. The severe disease is often associated with stroke, seizures, altered sensorium and ataxia, and more in patients with underlying medical comorbidities. These complications are immune-mediated, including the Guillain-Barré syndrome.[2]

A sizeable third of COVID-19 cases are reporting persisting symptoms, even after 6 weeks. These are also known as “Long COVID,” to describe the long-term effects of COVID-19, and it is feared that the “Long Covid” may itself become an epidemic.[3] Delayed neurological manifestation may also be a part of a “Long Covid.”[3] They may present as headaches, altered taste and smell, fatigue, sleep disturbance, and vague aches and pain. It is realized that those with neurodegenerative diseases are likely to fair poorer after SARS-CoV-2 infection.[4]

We have great pleasure in writing this editorial for the current issue of Apollo Medicine, which focuses on neurology and COVID-19 related articles. We have two original articles and four review articles, all concerning the recent advances which have taken place in the field of neurosciences in 2020. Rohatagi and Pandita[5] have discussed Multiple Sclerosis where the interest has been on promoting neuro-protection. They have presented the recent developments in the management of multiple sclerosis that is ushering recently (e.g., novel therapeutic disease- modifying agents like B cell therapies and sphingosine-1-phosphate inhibitors). Garg and Srivastava[6] have presented major advances in Amyotrophic Lateral Sclerosis (ALS). Recently, the launch of a treatment research initiative to cure ALS and the study of the biomarkers for biological activities. Mishra et al.[7] have given an insight into the diagnosis treatment and the latest advances in COVID-19 related mucormycosis. Mucormycosis is a life-threatening infection caused by fungi of the order Mucorales, and central nervous system involvement is usually an extension of the infection from the sinuses to the eyes and brain. A detailed account of the recent advances in stroke therapy has been provided by Renjen et al.,[8] who have elaborated about how the centers needed to modify their treatment in stroke patients due to COVID-19. Finally, the research in traumatic brain injury has been dealt with by Goda and Chandra,[9] wherein a crucial advance has been the development of diagnostic and prognostic biomarkers.

  References Top

Iyengar KP, Vaishya R. Long-term health consequences of COVID-19 disease. Apollo Med 2020;17 Suppl S1:32-5.  Back to cited text no. 1
Beghi E, Feigin V, Caso V, Santalucia P, Logroscino G. COVID-19 infection and neurological complications: Present findings and future predictions. Neuroepidemiology 2020;54:364-9.  Back to cited text no. 2
Iyengar KP, Jain VK, Vaishya R, Ish P. Long COVID-19: An emerging pandemic in itself. Adv Respir Med 2021;89:234-6.  Back to cited text no. 3
The Lancet Neurology. Long COVID: Understanding the neurological effects. Lancet Neurol 2021;20:247.  Back to cited text no. 4
Rohatgi A, Pandita N. Multiple sclerosis in 2020. Apollo Med 2021;18:196-9.  Back to cited text no. 5
  [Full text]  
Garg D, Srivastava AK. Major advances in amyotrophic lateral sclerosis in Apollo Med 2020. Apollo Med 2021;18:200-4.  Back to cited text no. 6
  [Full text]  
Mishra A, Chaudhari DM, Renjen PN. COVID-19–associated central nervous system mucormycosis. Apollo Med 2021;18:192-5.  Back to cited text no. 7
  [Full text]  
Renjen PN, Mishra A, Chaudhari DM. New frontiers in acute stroke management – A review. Apollo Med 2021;18: 166-71  Back to cited text no. 8
Goda R, Chandra PS. Advances in traumatic brain injury research in 2020: A review article. Apollo Med 2021; 18:172-8.  Back to cited text no. 9
  [Full text]  


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded106    
    Comments [Add]    

Recommend this journal